Fixed- or Controlled-Dose Mycophenolate Mofetil with Standard- or Reduced-dose Calcineurin Inhibitors: The Opticept Trial
Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Am J Transplant. 2009 Jul;9(7):1607-19
Mycophenolate mofetil is usually given at a fixed-dose post-transplant, with dose reductions made only for toxicity. This is the third randomized-controlled trial to assess a strategy of dose adjustment based on drug levels. Concentration-controlled MMF combined with lower-dose calcineurin inhibitors was non-inferior to fixed-dose MMF and standard-dose calcineurin inhibitors, with a trend to improved renal function but no difference in MMF-related adverse effects.
Related Articles:
- Everolimus with Very Low-Exposure Cyclosporine A in De Novo Kidney Transplantation: A Multicenter, Randomized, Controlled Trial
- Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients
- Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Recent Comments